Mecamylamine in Tourette's syndrome: A two-year retrospective case study

Journal of Child and Adolescent Psychopharmacology

Volumn 10, Issue 2, 2000, Pages 59-68

  Silver, Archie A ^a   Shytle, R Douglas ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; DIAZEPAM; FLUOXETINE; GUANFACINE; HALOPERIDOL; MECAMYLAMINE; NICOTINIC RECEPTOR BLOCKING AGENT; RISPERIDONE; SERTRALINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOOD; RATING SCALE; SCHOOL CHILD; SYNCOPE; VISUAL IMPAIRMENT;

EID: 0033913775     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2000.10.59     Document Type: Article

References (18)

1. Ahtee L, Kaakkola S: Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol. Br J Pharmacol 62:213-218, 1978
2. 3H]Mecamylamine binding to rat brain membranes: studies with mecamylamine and nicotine analogues. Biochem Pharmacol 40:2105-2110, 1990
3. Clark PBS, Hommer DW, Pert A, Skirboll LR: Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol 85:827-835, 1985
4. Dursun SM, Reveley MA, Bird R, Stirton F: Long-lasting improvement of Tourette's syndrome with transdermal nicotine [letter]. Lancet 344:1577, 1994
5. Hsu YN, Amin J, Weiss DS, Wecker L: Sustained nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes. J Neurochem 66:667-675, 1996
6. Kile JP, Turner BB: Serotonergic and cholinergic interaction in the regulation of pituitary-adrenal function in rats. Experientia 41:1123-1127, 1985
7. Lucas RJ, Ke L, Bencharef M, Eisenhour CM: Regulation by nicotine of its own receptors. Drug Dev Res 38:231-242, 1996
8. Martin BR, Martin TS, Fan F, Damaj MI: Central action of nicotine antagonists. Med Chem Res 2:564-577, 1993
9. NIMH: CGI (Clinical Global Impression) scale. Psychopharmacol Bull 21:839-843, 1985
10. Nisell M, Nomikos GG, Svensson TH: Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16:36-44, 1994
11. Pascualy M, Peskind ER, Wingerson D, van Belle G, Veith RC, Dorsa DM, Raskind MA: Lack of cholinergic regulation of vasopressin and norepinephrine responses to hypertonic saline in humans. Psychoneuroendocrinology 20:679-691, 1995
12. Sanberg PR, Shytle RD, Silver AA: Treatment of Tourette's syndrome with mecamylamine [letter]. Lancet 352:705-706, 1998
13. Sanberg PR, Silver AA, McConville BJ, Philipp MK, Gonzalez L, Cahill DW, Shytle RD: Nicotine as a therapeutic adjunct for Tourette's syndrome. In: K. Opitz (ed) Nicotine as a Therapeutic Agent. Vol. 10. Frankfurt, Germany, Foundation for Immunity and the Environment, 1997, pp. 35-41.
14. Shytle RD, Silver AA, Philipp MK, McConville BJ, Sanberg PR: Transdermal nicotine for Tourette's syndrome. Drug Dev Res 38:290-298, 1996
15. Silver AA, Sanberg P: Transdermal nicotine patch potentiates the therapeutic action of haloperidol in Tourette's syndrome. Lancet 342:182, 1993
16. Silver AA, Shytle RD, Sanberg PR: Clinical experience with transdermal nicotine in Tourette's syndrome. CNS Spectrums 4:68-76, 1999
17. Silver AA, Shytle RD, Philipp MK, Sanberg PR: Case study: Long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 35:1631-1636, 1996
18. Stone CA, Torchiana ML, Navarro A, Beyer KH: Ganglionic blocking properties of 3-methylaminoisocamphane HCl (mecamylamine): A secondary amine. J Pharmacol 117:169-183, 1956